Analysis of Treatment Compliance Level and the Relationship With Quality Of Life, New York Heart Association (NYHA) Classification, and Rehospitalization In Chronic Heart Failure Patients

Wenny Putri Nilamsari; Neni Tri Astuti; Wanudya  Atmajani; Budi  Suprapti; Hendri  Susilo

doi:10.53342/pharmasci.v11i1.565

Authors

Wenny Putri Nilamsari Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga
Neni Tri Astuti Master of Clinical Pharmacy Program Department of Pharmacy Practice, Universitas Airlangga, Surabaya, Indonesia
Wanudya Atmajani Master of Clinical Pharmacy Program Department of Pharmacy Practice, Universitas Airlangga
Budi Suprapti Department of Pharmacy Practice, Faculty of Pharmacy, Universitas Airlangga
Hendri Susilo Department of Cardiology, Teaching Hospital of Universitas Airlangga, Surabaya

DOI:

https://doi.org/10.53342/pharmasci.v11i1.565

Keywords:

Chronic Heart Failure,, Compliance,, Quality Of Life,, Nyha Classification,, Rehospitalization,

Abstract

Background: Patient non-compliance with heart failure treatment is associated with increased rehospitalization, deteriorating symptoms, decreased quality of life, and death. Therefore, this study aimed to examine compliance with chronic heart failure treatment and the relationship with quality of life, New York Heart Association (NYHA) classification, and rehospitalization.

Method: A cross-sectional study of chronic heart failure patients was carried out at Airlangga University Hospital (RSUA) from April to June 2023. The inclusion criteria include patients aged >18 years, signed informed consent, able to read, write, and had no difficulty communicating. Meanwhile, the exclusion criteria were chronic heart failure patients with no known history of rehospitalization.

Results: The results showed that 41% of heart failure patients were compliant with RAASi, beta-blockers, MRA, and furosemide. Compliance with RAASi had a positive relationship with NYHA classification. However, a negative relationship was found between overall medication compliance and rehospitalization. There was no relationship between RAASi, beta-blockers, MRA, and furosemide compliance with the incidence of rehospitalization.

Conclusion: A positive relationship was found between compliance and RAASi medication with NYHA classification, while medication compliance to the incidence of rehospitalization showed a negative relationship.

Keywords: Chronic Heart Failure, Compliance, Quality of Life, NYHA Classification, Rehospitalization

References

[1] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 42, no. 36, pp. 3599–3726, Sep. 2021, doi: 10.1093/eurheartj/ehab368.

[2] Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al., “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines,” Circulation, vol. 145, no. 18, pp. e895–e1032, 2022, doi: 10.1161/CIR.0000000000001063.

[3] Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al “Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017,” European Journal of Preventive Cardiology, vol. 28, no. 15, pp. 1682–1690, Dec. 2021, doi: 10.1093/eurjpc/zwaa147.

[4] Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, et al., “Heart failure around the world,” European J of Heart Fail, vol. 21, no. 10, pp. 1187–1196, Oct. 2019, doi: 10.1002/ejhf.1585.

[5] Groenewegen A, Rutten FH, Mosterd A, Hoes AW., “Epidemiology of heart failure,” European J of Heart Fail, vol. 22, no. 8, pp. 1342–1356, Aug. 2020, doi: 10.1002/ejhf.1858.

[6] Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al “Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019,” Journal of the American College of Cardiology, vol. 76, no. 25, pp. 2982–3021, Dec. 2020, doi: 10.1016/j.jacc.2020.11.010.

[7] Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al., “Heart failure: preventing disease and death worldwide,” ESC Heart Failure, vol. 1, no. 1, pp. 4–25, Sep. 2014, doi: 10.1002/ehf2.12005.

[8] Shimokawa H, Miura M, Nochioka K, Sakata Y, “Heart failure as a general pandemic in Asia,” European J of Heart Fail, vol. 17, no. 9, pp. 884–892, Sep. 2015, doi: 10.1002/ejhf.319.

[9] Brunton LL, Hilal-Dandan R, Knollmann BC., in Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 13e, New York, NY: McGraw-Hill Education, 2017.

[10] Ruppar TM, Cooper PS, Mehr DR, Delgado JM, Dunbar‐Jacob JM., “Medication Adherence Interventions Improve Heart Failure Mortality and Readmission Rates: Systematic Review and Meta‐Analysis of Controlled Trials,” JAHA, vol. 5, no. 6, p. e002606, Jun. 2016, doi: 10.1161/JAHA.115.002606.

[11] Tankumpuan T, Sindhu S, Perrin N, Commodore-Mensah Y, Budhathoki C, Padula W, et al.., “A Multi-Site Thailand Heart Failure Snapshot Study,” Heart, Lung and Circulation, vol. 31, no. 1, pp. 85–94, Jan. 2022, doi: 10.1016/j.hlc.2021.07.010.

[12] Dharmarajan K, Rich MW. “Epidemiology, Pathophysiology, and Prognosis of Heart Failure in Older Adults,” Heart Failure Clinics, vol. 13, no. 3, pp. 417–426, Jul. 2017, doi: 10.1016/j.hfc.2017.02.001.

[13] Seko Y, Kato T, Morimoto T, Yaku H, Inuzuka Y, Tamaki Y, et al.., “Association between changes in loop diuretic dose and outcomes in acute heart failure,” ESC Heart Failure, vol. 10, no. 3, pp. 1757–1770, Jun. 2023, doi: 10.1002/ehf2.14338.

[14] Lee HJ, Kim HK, Han KD, Lee K na, Park JB, Lee H, et al., “Age-dependent associations of body mass index with myocardial infarction, heart failure, and mortality in over 9 million Koreans,” European Journal of Preventive Cardiology, vol. 29, no. 10, pp. 1479–1488, Aug. 2022, doi: 10.1093/eurjpc/zwac094.

[15] Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, et al “Role of gender, age and BMI in prognosis of heart failure,” European Journal of Preventive Cardiology, vol. 27, no. 2_suppl, pp. 46–51, Dec. 2020, doi: 10.1177/2047487320961980.

[16] Khan MS, Samman Tahhan A, Vaduganathan M, Greene SJ, Alrohaibani A, Anker SD, et al, “Trends in prevalence of comorbidities in heart failure clinical trials,” European J of Heart Fail, vol. 22, no. 6, pp. 1032–1042, Jun. 2020, doi: 10.1002/ejhf.1818.

[17] Screever EM, Van Der Wal MHL, Van Veldhuisen DJ, Jaarsma T, Koops A, Van Dijk KS, et al. “Comorbidities complicating heart failure: changes over the last 15 years,” Clin Res Cardiol, vol. 112, no. 1, pp. 123–133, Jan. 2023, doi: 10.1007/s00392-022-02076-1.

[18] Rezaei S, Vaezi F, Afzal G, Naderi N, Mehralian G., “Medication Adherence and Health Literacy in Patients with Heart Failure: A Cross-Sectional Survey in Iran,” HLRP: Health Literacy Research and Practice, vol. 6, no. 3, Jul. 2022, doi: 10.3928/24748307-20220718-02.

[19] Jankowska-Polańska B, Świątoniowska-Lonc N, Sławuta A, Krówczyńska D, Dudek K, Mazur G., “Patient-Reported Compliance in older age patients with chronic heart failure,” PLoS ONE, vol. 15, no. 4, p. e0231076, Apr. 2020, doi: 10.1371/journal.pone.0231076.

[20] Bauersachs J., “Heart failure drug treatment: the fantastic four,” European Heart Journal, vol. 42, no. 6, pp. 681–683, Feb. 2021, doi: 10.1093/eurheartj/ehaa1012.

[21] Amininasab S, Lolaty H, Moosazadeh M, Shafipour V. “Medication adherence and its predictors among patients with heart failure,” Nurs Midwifery Stud, vol. 7, no. 2, p. 81, 2018, doi: 10.4103/nms.nms_9_17.

[22] Aggarwal B, Pender A, Mosca L, Mochari-Greenberger H., “Factors associated with medication adherence among heart failure patients and their caregivers,” JNEP, vol. 5, no. 3, p. p22, Dec. 2014, doi: 10.5430/jnep.v5n3p22.

[23] Garratt AM, Ruta DA, Abdalla MI, Buckingham JK, Russell IT, “The SF 36 Health Survey Questionnaire: An Outcome Measure Suitable For Routine Use Within The NHS?,” BMJ: British Medical Journal, vol. 306, no. 6890, pp. 1440–1444, 1993, Accessed: Aug. 02, 2025. [Online]. Available: http://www.jstor.org/stable/29719780

[24] Pallangyo P, Millinga J, Bhalia S, Mkojera Z, Misidai N, Swai HJ, et al.., “Medication adherence and survival among hospitalized heart failure patients in a tertiary hospital in Tanzania: a prospective cohort study,” BMC Res Notes, vol. 13, no. 1, p. 89, Dec. 2020, doi: 10.1186/s13104-020-04959-w.